Insulet

YTD

ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

CEO

James R. Hollingshead

CEOJames R. Hollingshead

Employees

3,000

Employees3,000

Headquarters

Acton, Massachusetts

HeadquartersActon, Massachusetts

Founded

2000

Founded2000

Employees

3,000

Employees3,000

PODD Key Statistics

Market cap

19.84B

Market cap19.84B

Price-Earnings ratio

48.93

Price-Earnings ratio48.93

Dividend yield

—

Dividend yield—

Average volume

667.68K

Average volume667.68K

High today

$286.66

High today$286.66

Low today

$274.87

Low today$274.87

Open price

$276.04

Open price$276.04

Volume

1.39M

Volume1.39M

52 Week high

$289.46

52 Week high$289.46

52 Week low

$160.19

52 Week low$160.19

PODD News

TipRanks 22h

Insulet’s Financial Challenges: Navigating Pandemic Risks and Cybersecurity Threats

Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Discover the Best Stocks and Maximize Your Portfolio: See what stocks...

Benzinga 1d

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. The automat...

Simply Wall St 1d

Insulet (NasdaqGS:PODD) Reports Q4 Earnings and Offers 2025 Revenue Growth Guidance

recently issued strong revenue guidance for the first quarter and full year of 2025, anticipating significant growth across its Omnipod product lines despite ch...

Analyst ratings

83%

of 24 ratings

Buy

83.3%

Hold

12.5%

Sell

4.2%

More PODD News

TipRanks 2d

Insulet price target raised to $310 from $285 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Insulet (PODD) to $310 from $285 and keeps an Overweight rating on the shares. The firm not...